newsfilter
← Latest News
Business Wire·

Pear Therapeutics Reports First Quarter 2022 Financial Results

108% quarter-over-quarter revenue growth to $2.7 million >9,200 total prescriptions in the first quarter for Pear's three FDA-authorized products Expanded patient access with state payors in Michigan and Oklahoma CMS issued new HCPCS code